Related Experiment Videos
Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia
J U Hedlund1, M E Kalin, A B Ortqvist
1Department of Infectious Diseases, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Insights
Pneumococcal vaccination after hospital treatment for pneumonia in middle-aged and elderly patients generates an adequate antibody response. This approach appears safe and effective for preventing future pneumococcal infections.
Area of Science:
- Immunology
- Infectious Diseases
- Vaccinology
Background:
- Recurrent pneumonia is common in hospitalized patients, indicating a need for preventative strategies.
- Pneumococcal vaccination may prevent subsequent pneumococcal infections in at-risk populations.
- Previous hospital treatment for pneumonia is a significant risk factor for recurrence.
Purpose of the Study:
- To evaluate the type-specific antibody response to pneumococcal vaccine.
- To assess vaccine efficacy in middle-aged and elderly patients post-hospitalization for pneumonia.
- To determine the safety and immunogenicity of pneumococcal vaccination at 8-week follow-up.
Main Methods:
- 92 individuals (50-85 years) were studied, divided into those recently treated for pneumonia (n=65) and a control group (n=27).
- All participants received a single dose of a 23-valent pneumococcal vaccine.
- Enzyme-linked immunosorbent assay (ELISA) measured type-specific antibody responses to key pneumococcal antigens before and after vaccination.
Main Results:
- Antibody concentrations and fold increases post-vaccination were similar between the pneumonia patient group and the control group.
- No significant differences in antibody response were observed between the two groups.
- No serious adverse events were reported during the study.
Conclusions:
- Pneumococcal vaccination administered 8 weeks after hospital pneumonia treatment is immunogenic in middle-aged and elderly individuals.
- The vaccine elicits an adequate antibody response in this patient population.
- The vaccination strategy appears safe, with no significant adverse reactions observed.
Background:
A substantial proportion of patients admitted to the hospital for pneumonia have been treated in a hospital during the preceding 4 to 5 years, and patients previously treated in a hospital for pneumonia seem to be at an especially high risk for another episode of pneumonia. Many cases of pneumococcal infection might therefore be prevented by immunizing admitted patients with pneumococcal vaccine at discharge or at follow-up. The aim of this study was to investigate the type-specific antibody response to pneumococcal vaccine in middle-aged and elderly patients at follow-up 8 weeks after hospital treatment for pneumonia.
Methods:
A total of 92 individuals, 50 to 85 years old, participated in the study. One group consisted of 65 individuals treated in the hospital for pneumonia 8 weeks before vaccination (mean age, 67 years), and another group consisted of 27 individuals who had not recently been treated for pneumonia (mean age, 67 years). All 92 individuals received a single dose of a 23-valent pneumococcal vaccine. The type-specific antibody responses to six pneumococcal capsular polysaccharide antigens included in the vaccine as well as antibodies against the 23-valent pneumococcal vaccine were measured before and 3 to 4 weeks after vaccination by use of an enzyme-linked immunosorbent assay.
Results:
The antibody concentrations before and after vaccination were comparable in the two groups, as were antibody fold increases from prevaccination to postvaccination serum. No serious adverse events were recorded.
Conclusions:
Pneumococcal vaccination at follow-up 8 weeks after treatment in the hospital for pneumonia seems to elicit an adequate antibody response without notable adverse reactions.